Company Encyclopedia
View More
name
Cognition Therapeutics
CGTX.US
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
4.673 T
CGTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cognition Therapeutics Reaches Full Enrollment in Zervimesine Expanded Access Program for Dementia with Lewy Bodies

    Cognition Therapeutics Inc. has achieved full enrollment in its expanded access program for zervimesine (CT1812) for dementia with Lewy bodies. Participants will receive a daily 100 mg dose for up to a year. The program, funded by a donation, completed enrollment in three months. A Type C meeting with the FDA is scheduled for January to discuss a Phase 3 program. No new scientific results were announced.

    Reuters·
    US
    CGTX
    +3.25%
    Reuters·
    US
    CGTX
    +3.25%

    Cognition Therapeutics Announces Phase 3 Trials of Zervimesine for Mild-to-Moderate Alzheimer's Disease

    Cognition Therapeutics Inc. announced a Phase 3 registrational program for zervimesine (CT1812) in adults with mild-to-moderate Alzheimer’s disease. The study, supported by the FDA, will enroll participants with lower plasma p-tau217 levels and consist of two six-month studies. Efficacy will be measured using the iADRS scale. Phase 2 results showed zervimesine slowed cognitive decline. Details were presented at the CTAD conference. Cognition Therapeutics is also seeking EMA alignment for global plans.

    Reuters·
    US
    CGTX
    +3.25%
    Reuters·
    US
    CGTX
    +3.25%

    Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

    Cognition Therapeutics, Inc. (NASDAQ:CGTX) has received a consensus rating of "Moderate Buy" from five brokerages. The stock has one sell rating, three buy ratings, and one strong buy rating. The average twelve-month price target is $3.3333. Recent ratings include B. Riley's buy rating with a $3.00 target and Chardan Capital's buy rating with a $4.00 target. The stock is currently trading at $1.39. Institutional investors hold 43.35% of the company's stock.

    Market Beat·
    US
    CGTX
    +3.25%
    Market Beat·
    US
    CGTX
    +3.25%

    Cognition Therapeutics Completes Enrollment in Phase 2 Trial of Zervimesine for Early Alzheimer’s Disease

    Cognition Therapeutics Inc. has completed enrollment for its Phase 2 START study of zervimesine (CT1812) for early Alzheimer's disease. The study, involving 540 participants, aims to assess the safety and activity of the drug, with results expected after 18 months of treatment. The trial is conducted with the Alzheimer's Clinical Trials Consortium, and some participants are also receiving Leqembi or Kisunla. Previous Phase 2 results were presented in 2025.

    Reuters·
    US
    CGTX
    +3.25%
    Reuters·
    US
    CGTX
    +3.25%

    Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

    - $30 Million Registered Direct Offering Support Next Stage of Development for ...

    GlobeNewswire·
    US
    CGTX
    +3.25%
    GlobeNewswire·
    US
    CGTX
    +3.25%
    © 2025 Longbridge｜Disclaimer